NovaBay Pharmaceuticals, Inc. (NYSE:NBY) is struggling to gain traction with investors, as evidenced by its 12362507 shares volume. The daily trading volume average remained 2637100 shares over the course of 5 days. The stock had opened the regular trading at $1.45 and managed a 34.31% price change to reach $1.37 through the close.

NovaBay Pharmaceuticals, Inc. (NBY) Analyst Opinion

NovaBay Pharmaceuticals, Inc. is currently rated as outperform by 2 stock analysts, with the company still having around 4.75% shares outstanding that can be sold short legally. The value of their shares went down by -20.81% last month. Over the course of a year, the stock has grown by 77.3%. Financial analysts are becoming more bullish than ever, with the 1 analysts who cover the activities of NBY advising investors to buy. Experts on Wall Street have set a price target of $1.25 for the stock. The decision was arrived after looking at their -8.76% decline from current levels. At the moment, NovaBay Pharmaceuticals, Inc. (NBY) trading price is around -66.09% below its 52-week high.

NovaBay Pharmaceuticals, Inc. Earnings Surprise

NovaBay Pharmaceuticals, Inc. (NBY) was unsuccessful in overcoming the expected -$0.12 as the stock recorded an earnings of -$0.28 a piece during their last financial report presentation. Revenue, meanwhile, had a distance of -42.27% from the previous quarter, with the company recording $2.09 million in revenue.

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Intraday View

The shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) have struggled and recovered 498.25% ever since it recorded its 52 week low. During the course of 5 days, the stock price volatility has remained at 11.54%, increasing the time frame to a month, the volatility recorded was 9.87%. The price of their shares still hasn’t been successful in staying above its 20 day-moving average, staying at a distance of -1.01% and while its 50-day moving average is around 12.87%. In a look at the previous five trading session NBY stock has returned 17.09% and has spiked 10.81% when compared to its 200-day moving average that is $1.2436. NovaBay Pharmaceuticals, Inc. (NBY) will look to overcome its -41.45% fall that it witnessed in the past year.

As the normal trading session ended, the stock of OPKO Health, Inc. (NASDAQ:OPK), fetched in a $-0.03 retreat to $2.1. The session began with the stock price at $2.08, hitting a high of $2.11 before down again. For the week, analysts seem to be okay with their bullish with the consensus call staying at 1.3. OPKO Health, Inc. gets 1 buy analyst recommendations while 0 recommend a hold and 0 rated it as a sell. The shares of the company tumbled -65.91% from its high $6.16, with their overall market value now roughly $1.26 billion.

OPKO Health, Inc. (OPK) Consensus Price Target

The mean recommendation of OPK on Reuter’s scale remained unchanged from 1.67 to 1.67 within 30 days. This figure implies that the majority of analysts rate it as a buy. The price target for OPKO Health, Inc. (NASDAQ:OPK) is now around $5 a share, implying the stock has what it takes to grow by 138.1%. The recent trading session also indicated the stock needs to add 185.71% more meet analysts’ high consensus price target.

OPKO Health, Inc. (NASDAQ:OPK) Intraday Trading

The current trading volume of the company was 3768654 shares during the last session. That compares with the recent average volume of 2828960 shares. By the end of the regular trading session, the price volatility over a 1-week span was 4.04 % while over a month it stood at 4.6%. The stock price of OPK dropped to $2.02 during the day and at a certain time in 12 months it traded as low as $1.73. It has made a 21.39% recovery since its 52-week low point and has returned -30.23% year-to-date. [T3]